PatenSee notes the trial will evaluate the system’s ability to perform contact-free surveillance of fistula stenosis similar to a nurse’s physical exam of hemodialysis patients.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
